37 results
8-K
EX-10.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
) with responsibility for evaluating the cost effectiveness of medicinal products in the United Kingdom (or one or more constituent countries thereof … have the right at its absolute discretion to assume responsibility for the further prosecution and maintenance of any such Patent at CRH’s cost
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
Person that has been delegated responsibility for achieving the Milestone or for the development, Regulatory Approval or commercialization of any Product … Liabilities shall remain the sole responsibility of and be retained, paid, performed and discharged solely by Seller:
(ii)
(iii)
(iv)
(vi)
(vii
DEFM14A
ELYM
Eliem Therapeutics Inc
4 Jun 24
Proxy related to merger
8:00am
appropriate.
Leerink Partners assumed, without independent verification or any responsibility therefor, the accuracy and completeness … as of, the date of its written opinion, and Leerink Partners does not have any obligation or responsibility to update, revise or reaffirm its
opinion based
PREM14A
ELYM
Eliem Therapeutics Inc
17 May 24
Preliminary proxy related to merger
4:36pm
Partners deemed appropriate.
Leerink Partners assumed, without independent verification or any responsibility therefor, the accuracy and completeness … Partners as of, the date of its written opinion, and Leerink Partners does not have any obligation or responsibility to update, revise or reaffirm its
DEFA14A
oune1
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-2.1
z9t3 drqu4
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
S-8
EX-5.1
yw5mj0gotw4f7
28 Mar 24
Registration of securities for employees
4:27pm
DEF 14A
xows mxxj9jqlo5s
8 Apr 22
Definitive proxy
4:20pm
10-K
wp06 xw7ky7
7 Mar 22
Annual report
4:03pm
10-Q
jlt5bk
13 Sep 21
Quarterly report
4:01pm